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Summary 
What is known: High D-dimer levels are seen in patients with severe COVID-19 infection. Increased rates of 
Venous thromboembolism (VTE) have been reported in COVID-19 patients admitted to critical care. 
What is the question: What is the rate of VTE in hospitalised patients with COVID-19? What are the risk factors 
associated with VTE in hospitalised COVID-19 patients? 
What was found: 21/274 (7.7%) COVID-19 patients were diagnosed with VTE. Most COVID-19 patients had 
elevated (>0.5 µg/mL) D-dimers (56/60, 93%), however, levels were higher in patients with VTE (4.1 vs 1.2 µg/mL 
P <0.001). 
Implications for practice: Clinicians should be vigilant for VTE in patients with COVID-19 infection and ensure 
prophylactic measures are in place. Very high D-dimer levels should increase clinical suspicion of venous 
thromboembolism.   
 
Abstract 
Background: A possible association between COVID-19 infection and thrombosis, either as a direct consequence of 
the virus or as a complication of inflammation, is emerging in the literature. Data on the incidence of venous 
thromboembolism (VTE) is extremely limited. 
Methods: We describe 3 cases of thromboembolism refractory to heparin treatment, the incidence of VTE in an 
inpatient cohort, and a case-control study to identify risk factors associated with VTE. 
Results: We identified 274 confirmed (208) or probable (66) COVID-19 patients. 21 (7.7%) were diagnosed with 
VTE. D-dimer was elevated in both cases (confirmed VTE) and controls (no confirmed VTE) but higher levels were 
seen in confirmed VTE cases (4.1vs 1.2 µg/mL P <0.001). 
Conclusion: Incidence of VTE is high in patients hospitalised with COVID-19. Urgent clinical trials are needed to 
evaluate the role of anticoagulation in COVID-19. Monitoring of D-dimer and anti-factor Xa levels may be 
beneficial in guiding management. 
Introduction 
Novel coronavirus SARS-CoV-2 emerged in late 2019 and has spread rapidly around the world. On 12/3/2020 the 
World Health Organisation declared a pandemic [1]. Severe COVID-19 infection may predispose individuals to 
thrombotic events or coagulopathy [2-4] possibly mediated by excessive inflammation or direct virus effect Poor 
outcomes have been observed in association with raised D-dimers [3,5] whilst anticoagulation may reduce disease 
mortality [6]. Data on the incidence of venous thromboembolism (VTE) are currently limited. 
We identified an increased incidence of VTE amongst inpatients admitted with COVID-19. Additionally, several 
individuals appeared refractory to therapeutic anti-coagulation with heparin. Based on these observations we 
identified a consecutive series of hospital patients diagnosed with COVID-19 infection between 20/3/20 and 9/4/20 
(274), and observed the rate of venous thromboembolic disease (21). 
We describe the pertinent clinical features of 3 patients diagnosed with COVID-19 and venous thromboembolism 
who appeared refractory to initial treatment with heparin. A retrospective case-control design was used to identify 
significant clinical characteristics associated with VTE in patients admitted with COVID-19. 
Methods 
Clinical Setting 
This study was carried out at the Brighton and Sussex University Hospitals NHS trust including 2 acute hospital sites 
in southern England.  
COVID-19 data  
Patients were identified as having confirmed or probable COVID-19 if they had PCR-detected SARS-CoV2 respiratory 
sample, or a chest X-ray (CXR) or computed tomography (CT) scan that was consistent with COVID-19 or probable 
COVID-19 according to a standardised imaging reporting protocol that was introduced on the 20th March 2020. 
Records for all positive SARS-CoV2 virology between 20/3/2020 and 9/4/2020 were obtained from the laboratory 
inpatient management system (Winpath, Clinisys, Chertsey, UK). Records of all imaging reported as consistent with 
COVID-19 or probable COVID-19 between 20/3/2020 and 9/4/2020 was obtained from the picture archiving and 
communication system (Intellispace PACS, Philips, Amsterdam, NL). 
Clinical data 
Hospital admissions were identified using the patient administration system (Medway, System C, Maidstone, UK). 
For those patients admitted to hospital, admission blood test results were obtained from the laboratory inpatient 
management system (ICE, Sunquest, Tucson, US). Data on patients’ past medical history was obtained by screening 
discharge summaries from the Patient Administration System (Medway, System C, Maidstone, UK). This system was 
also used to identify all patient deaths, of any cause, up to 18/4/20. Records of all imaging reported as 
demonstrating VTE, including pulmonary embolism (PE) and deep vein thrombosis (DVT), from 20/3/2020 up to the 
16/4/2020 was obtained from the PACS. Only patients with confirmed radiologically confirmed VTE, including DVT 
and PE were included. Data was collected on age, sex, critical care admission, and co-morbidities (history of 
cardiovascular, pulmonary, renal or malignant disease, diabetes, immunocompromise or immunosuppressive 
treatment). Admission blood results were collected for total white cell count, lymphocyte count, CRP, D-dimer, INR, 
APTT ratio and fibrinogen. 
Case-control study 
The case-control group was constructed at a ratio of 1:2, cases to controls. A case was defined as having imaging 
positive for venous thromboembolism and either a respiratory tract sample PCR positive for SARS-CoV-2 or imaging 
consistent with the diagnosis of COVID-19 pneumonia. 3 cases did not have a D-dimer, APTT ratio or fibrinogen 
result recorded but had their other results included in the analysis. Control patients were identified from inpatients 
sequentially diagnosed either radiologically or via PCR without evidence of venous thromboembolism as of 16/4/20. 
The ratio of PCR positive to PCR negative patients was matched between cases and controls. Control patients were 
excluded if clinical information was incomplete. 
Statistical analysis  
Statistical analysis was performed using Prism 8 (GraphPad Software, San Diego, US). Categorical variables were 
analysed by Z-test. Means of normally distributed continuous variables were compared by unpaired T-test. Means of 
non-normally distributed variables were compared by Mann-Whitney test. A logistic regression model was 
constructed to test the strength of association between clinical variables and the presence of venous 
thromboembolism. Results were considered significant if the P-value was <0.05. 
Ethics 
Informed consent was obtained from the patients in the case series. 




Table 1 describes the clinical characteristics of 3 patients who were admitted with type 1 respiratory failure and 
diagnosed with COVID-19 infection. All 3 cases demonstrated persistent hypoxia and were subsequently diagnosed 
with VTE. Despite weight-based treatment with low molecular weight heparin, all patients demonstrated either sub-
therapeutic anti-factor Xa levels or clinical progression of clot. 
To determine the incidence of VTE amongst inpatients with COVID-19 pneumonia, we examined records of a 
consecutive series of inpatients with confirmed or possible COVID-19 infection from the 20th March to the 9th April 
2020, 274 hospital inpatients with confirmed or possible COVID-19 infection were identified. Of these, 208 out of 
274 (76%) patients had a diagnosis of COVID-19 confirmed by PCR on a respiratory specimen and 66 out of 274 (24%) 
had a probable diagnosis, with imaging consistent with COVID-19. A total of 21 out of 274 (7.7%) patients were 
diagnosed with venous thromboembolism up to 16/4/2020. 16 out of 21 (76.2%) patients were diagnosed with PE 
and 5 out of 21 (23.8%) were diagnosed with DVT. We found a small but non-significant difference in the rate of VTE 
between patients with a confirmed diagnosis of COVID-19 and those with a probable (imaging confirmed) diagnosis 
of COVID-19 (14/208 [6.7%] vs 7/66[10.6%], P=0.07). As of 18/4/2020, the overall all-cause mortality rate in our 
cohort was 76 out of 274 (27.7%). Significantly more deaths occurred in patients who were PCR positive compared to 
those who were diagnosed radiologically (66/208 [31.7%] vs 10/66 [15.2%], P=0.01). However, outcome data is 
incomplete as not all patients have yet recovered fully from their disease. 
21 patients with thromboembolism were identified as cases and 42, without evidence of thromboembolism, 
identified as controls. Their clinical features are summarised in Table 2. We found significant differences in levels of 
D-dimer (4.1 vs 1.2 µg/ml P<0.001) and white cell count (11.1 vs 7.2 x109/L P=0.009). There was a small, but 
statistically significant difference in baseline INR (1.1 vs 1.05 P=0.02). There were no significant differences in age, 
gender or presence of comorbidities between the two groups. 
Using multiple logistic regression modelling with adjustment for age, sex and SARS-CoV-2 swab PCR positivity we 
found a significant association between white cell count (OR 1.18 P=0.03) D-dimer (OR 1.39 P=0.004) and fibrinogen 
(OR 1.66 P=0.03) with the occurrence of VTE in COVID-19 patients (Table 3). Although the odds ratio of VTE appeared 
higher for female sex (3.55), it was not statistically significant (P=0.12) 
To further examine the positive association between D-dimer and VTE, we stratified patients according to D-dimer 
result (Table 4). Almost all patients had an abnormal D-dimer result at baseline, defined as a D-dimer >0.5 µg/mL 
(17/18, 94% VTE positive patients vs 39/42 VTE negative patients, OR 1.3 P=0.82) however a D-dimer threshold of >2 
µg/mL was present in 14/18 (78%) of patients with VTE and only 14/42 (33%) patients without VTE (OR 7 P=0.002). 
Discussion 
A number of observational studies have alluded to the presence of coagulopathy in severe COVID-19 patients, 
including abnormal clotting parameters and the presence of overt DIC [2-5].  A recent pooled analysis by Lippi and 
Favaloro highlighted an association between D-dimer and severe COVID-19 infection [5]. Tang and colleagues 
described an association between heparin use and survival in patients with a high ‘sepsis-induced coagulopathy’ 
(SIC) score or D-dimer [6]. Despite these observations reports of thrombotic complications are limited. Klok and 
colleagues report on the incidence of thrombotic complications (both arterial and venous) in critical care patients in 
2 Dutch university hospitals and found an overall rate of 31% [8]. Cui et al report a DVT incidence of 25% among 81 
intensive care patients [9]. The data described here supports previous findings, that D-dimer is markedly elevated in 
patients with COVID-19 infection, and provides the first peer-reviewed quantitative analysis of venous 
thromboembolism including adult patients with COVID-19 infection outside of an intensive care setting. We highlight 
the possibility that some individuals infected with COVID-19 may be refractory to treatment with low molecular 
weight heparin. Reports of the use of thrombolysis in these patients remain scanty within the literature [10]. 
Our analysis included patients with probable COVID-19 infection based on radiological findings. We found that 66 
out of 274 (24.1%) of our patients were PCR negative on upper respiratory tract samples but had a clinical syndrome 
consistent with COVID-19 infection. Previous authors have observed that clinical deterioration often occurs late in 
disease [4]; at this time, upper respiratory tract samples may be negative [11, 12]. Consistent with these findings we 
saw a tendency towards higher rates of VTE in patients who were PCR negative, although the differences were not 
statistically significant and there was no significant association between PCR status and the presence of VTE in the 
multivariate analysis (Table 3). It should be noted that there is a difference in mortality between those with 
radiologically diagnosed COVID-19 and those who were diagnosed by PCR. It is possible some of the patients in the 
radiology arm had an alternative diagnosis. It is difficult to speculate on the mortality difference due to the 
incomplete period of follow-up. 
D-dimer, a breakdown product of fibrin, is elevated in the acute phase of the inflammatory response [13]. What 
remains unclear is whether rate of VTE described here is attributable specifically to COVID-19 infection or, 
alternatively, is representative of patients with a profound inflammatory response. Severe COVID-19 infection has 
been associated with markedly elevated inflammatory markers [2, 4, 13, 15, 16]. We found significantly higher levels 
of circulating white cells and fibrinogen, but not CRP, in patients who developed VTE compared to those with no VTE 
(Table 2, Table 3). Outside of COVID-19 infection, several authors have described an association between thrombotic 
risk and circulating levels of inflammatory markers including CRP and pro-inflammatory cytokines, notably IL-6 and 
IL-8 (16-18), although data in acute inflammation is lacking. Given our small sample size, it is possible our study was 
underpowered to detect differences in CRP. Notably high rates of thromboembolism are seen with ARDS and severe 
pulmonary infection [19]. Data on incidence of venous thromboembolism with specific viral respiratory infections is 
limited. However, one case series identified a rate of 3.4% amongst 119 hospitalised patients with H1N1 influenza 
[20]. 
The role of therapeutic anticoagulation, particularly in ARDS and severe sepsis, continues to be debated [19, 21-24].  
Blockade of the ACE2 receptor, the receptor by which SARS-CoV-2 enters cells via S-spike binding [25] has been 
associated with inflammatory effects [26]. ACE2 is expressed on vascular endothelium [27]. In the case series, levels 
of von Willebrand factor (vWF)and factor VIII were extremely high. This may be attributable to viral disruption of the 
endothelium leading to release of vWF from the Weibel-Palade storage bodies and exposing underlying collagen 
with release of prothrombotic mediators resulting in increased fibrin turnover and hypercoagulability, and requires 
further investigation. 
Overall, these data confirm that D-dimer levels are raised in most hospitalised patients with COVID-19 infection and 
may be associated with increased rates of venous thromboembolism. Although rates of thromboembolism were high 
in this series, we suspect overall rates of VTE may be under-diagnosed in COVID-19 pneumonia. Within our hospitals 
we have introduced D-dimer levels as a routine investigation in all suspected COVID-19 patients to support the 
detection of VTE. In addition, we are measuring anti-factor Xa levels in patients diagnosed with VTE on treatment 
dose anticoagulation to ensure therapeutic dosing. Urgent clinical trials are required to investigate the role of 
enhanced prophylactic and therapeutic anticoagulation in these patients as a way of abrogating the high levels of 
mortality seen in hospitalised COVID-19 patients. 
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Characteristic Case 1 Case 2 Case 3 
Age 49 81 60 
Comorbidities  Asthma and bronchiectasis  COPD, Hypertension Prostate cancer 
Sex Male Female Male 
Length of illness prior to 
admission date (days) 
23 18 2 
Symptoms at onset Dry cough, fever, anosmia, 




Imaging features Patchy peripheral airspace 
opacification on CXR 
Bilateral multifocal 
consolidation on CXR 
Bilateral ground glass 
opacification on CT. 
Clinical course Following admission with 
type 1 respiratory failure 
and pleuritic chest pain a 
CTPA was performed on 
day 2 demonstrating 
bilateral pulmonary emboli.  
Due to low anti-factor Xa 
levels despite treatment 
with tinzeparin (175 
Units/kg) he was switched 
to Enoxaparin 1mg/kg BD. 
Admitted with type 1 
respiratory failure 
tachycardia and fever. 
Persistent tachycardic and 
hypoxic on day 3 of 
admission. a CTPA 
demonstrated extensive 
bilateral pulmonary emboli. 
Due to low anti-factor Xa 
levels despite treatment 
with tinzeparin (175 
Units/kg) she was switched 
to Enoxaparin 1mg/kg BD. 
Intubated in emergency 
department due to 
profound hypoxia. On day 8 
lower limb swelling noted. 
USS diagnosed common 
and superficial femoral vein 
thrombus. Despite 
intravenous heparin the 
APTT ratio was 
subtherapeutic. Switched 
to argatroban and clinically 
improved to discharge from 
critical care. 
Critical care admission N N Y 
VTE PE PE DVT and PE 
Laboratory Findings on 
admission 
   
Positive PCR for SARS-CoV-2 N N Y 
WCC 10
9
/L 12.1 8 11.2 
Lymphocyte count 10
9
/L 1.2 0.4 0.3 
CRP mg/L 367 58 247 
INR 1.2 1.1 1.1 
APTT ratio 1.2 1 1.2 
Fibrinogen g/L 9.9 7.3 6.8 
D Dimer ug/ml FEU 3.32 3.31 19.38 
Troponin ng/L 5.19 - 269 
Special Haematology    
Initial Anti Xa IU/ml (0.4-1.0) 0.3 0.38 - 
Repeat Anti Xa IU/ml 0.41 0.52 - 
Antithrombin  % (84-119) 84 99 74 
Von Willebrands Factor Antigen 
% (50-140) 
338 210 762 
Factor VIIIc u/dL (60-150) 341 205 506 
Table 1: Case series. APTT = activated partial thromboplastin time, CRP= C-reactive protein, DVT = Deep vein 







 Inpatients with COVID-19 
 VTE Positive  
(N=21) 
VTE Negative  
(N=42) 
P-value 
Age [Mean (SD)]* 67 (12) 65 (15) 0.32 
Female Sex [n (%)] 7 (33) 18 (43) 0.47 
Comorbidities  
   Cardiovascular disease [n (%)] 6 (29) 9 (21) 0.53 
   Diabetes [n (%)] 8 (38) 10 (23) 0.23 
   Pulmonary Disease  [n (%)] 8 (38) 9 (21) 0.16 
   Renal Disease [n (%)] 4 (19) 6 (14) 0.63 
   Malignancy [n (%)]) 4 (19) 6 (14) 0.63 
   Immunosuppression [n (%)] 2 (10) 3 (7) 0.74 
Admission to Critical Care [n (%)] 6 (29) 14 (33) 0.70 
Laboratory parameters  
   CRP mg/L [Median (IQR)] 122 (188) 78.5 (101) 0.09 
   White Cell Count x109/L [Median (IQR)] 11.1 (4.6) 7.2 (4.5) 0.009 
   Lymphocytes x109/L [Median (IQR)] 0.9 (0.7) 0.9 (0.6) 0.95 
   D-Dimer µg/mL [Median (IQR)] 4.1 (6.0) 1.2 (2.0) <0.001 
   APTT ratio [Median (IQR)] 1.1 (0.1) 1.2 (0.3) 0.72 
   Fibrinogen g/L [Mean (SD)]* 6.8 (2.2) 6.6 (1.8) 0.7 
   INR [Median (IQR)] 1.1 (0.2) 1.05 (0.1) 0.02 
Table 2: Clinical characteristics of case-control sample. Sequentially diagnosed patients without VTE diagnosis as of 
9/4/20 were selected as controls at a ratio of 2:1. 3 Cases without measurements of D-dimer, APTT ratio or 
Fibrinogen were included in the analysis. Control patients were excluded if data was incomplete. Control patients 
were selected at a ratio of 2:1 swab positive (28) to swab negative (14) to match the distribution of cases. D-dimer 
above 20 was recorded as 20 for the purposes of analysis. Normally distributed data is marked with an *. Proportions 
were analysed by Z-test, normally distributed variables by unpaired T-test and non-parametric variables by Mann-
Whitney test. APTT = activated partial thromboplastin time, CRP= C-reactive protein, INR = International normalised 
ratio, IQR = interquartile range, SD = Standard deviation, VTE = venous thromboembolism. 
 
 Multivariate analysis  
Predictor Variables Odds Ratio 
(95% CI) 
P-value 
Age  0.96 
(0.91 – 1.02) 
0.22 
Female Sex  3.55 
(0.78 – 19.6) 
0.12 
White Cell Count (x109/L) 1.18 
(1.02 – 1.40) 
0.03 
D-Dimer (µg/mL) 1.39 
(1.15 – 1.84) 
0.004 
Fibrinogen (g/L) 1.66 
(1.07 – 2.73) 
0.03 
SARS-CoV-2 PCR positive 0.98 
(0.23 – 4.59) 
0.98 
Table 3: Multivariate analysis using logistic regression for factors associated with the presence of VTE. Non-















D-dimer >0.5 [n (%)] 17 (94) 39 (92) 1.3 
(0.18 – 17.9) 
0.82 
D-dimer >1 [n (%)] 17 (94) 27 (64) 9.4 
(1.41 – 105) 
0.02 
D-dimer >2 [n (%)] 14 (78) 14 (33) 7.0 
(1.95 – 21.6) 
0.002 
D-dimer >3 [n (%)] 12 (67) 10 (24) 6.4 
(1.87 – 19.3) 
0.002 
D-dimer >4 [n (%)] 9 (50) 8 (19) 4.3 
(1.32 – 14.2) 
0.01 
Table 4: Stratified univariate analysis using pragmatic D-dimer cut-offs. Statistical significance was determined by 
Chi-squared test. VTE = venous thromboembolism. 
 
 
